Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CTMX
#2642
CytomX Therapeutics, Inc.
4.4
2
USD
+0.68%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.68%
Monthly Change
-36.03%
6 month change
+27.75%
Year Change
+612.90%
Previous Close
4.3
9
Open
4.4
0
Bid
Ask
Low
4.3
9
High
4.4
5
Volume
122
Markets
US Stock Market
Healthcare
CTMX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
64.78 M
65.39 M
66.23 M
67.72 M
80.1 M
170.19 M
—
Valuation ratios
Enterprise value
232.48 M
77.62 M
-87.02 M
97.28 M
44.45 M
712.33 M
1.55 B
Price to earnings ratio
—
—
-1.07
-169
2.71
-28.4
-15.05
Price to sales ratio
—
—
1.99
1.23
0.63
7.71
12.15
Price to cash flow ratio
—
—
-0.96
-2.23
-1.01
-7.77
-15.75
Price to book ratio
—
—
-1.23
-2.63
-191.42
5.93
8.31
Enterprise value to EBITDA ratio
-5.02
-0.96
0.88
-8.27
2.07
-30.67
1.18
Profitability ratios
Return on assets %
-0.09
-0.25
-0.38
-0
0.26
-0.11
-0.03
Return on equity %
-0.66
-0.94
1.16
0.01
-69.89
-0.18
0.54
Return on invested capital %
-137.42
-322.4
-333.03
2.95
82.29
-145.89
-351.48
Gross margin %
100
100
100
100
100
100
400
Operating margin %
-48.43
-120.42
-190.61
-6.41
18.1
-29.35
-4 439.72
EBITDA margin %
-46.13
-116.08
-186.11
-11.62
15.52
-30.48
-4 537.54
Net margin %
-32.77
-120.17
-186.82
-0.56
23.08
-22.79
-4 191.74
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
3.21
2.92
1.55
1.17
1.25
3.09
12.65
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.29
0.2
0.18
0.44
0.86
0.56
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-1.69
-0.76
-1.02
-0.55
-0.63
EBIT per share
—
—
-1.54
-0.09
0.29
-0.16
-0.05
EBITDA per share
—
—
-1.51
-0.16
0.25
-0.17
-0.06
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
1.45
2.38
1.2
0.99
4.01
Net current asset value per share
—
—
3.61
2.48
1.27
1.04
4.22
Tangible book value per share
—
—
-1.33
-0.67
-0.02
0.71
2.54
Working capital per share
—
—
1.29
0.37
0.25
0.71
2.75
Book value per share
—
—
-1.3
-0.64
-0.01
0.72
2.59
News
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts - TipRanks.com
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTMX) 2026-03-17
CytomX launches $250M public offering to fund drug development
Micron and Intel among market cap stock movers on Monday
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) (CTMX)
Micron, Intel among market cap stock movers on Monday
CytomX Therapeutics Inc earnings missed by $0.24, revenue fell short of estimates
Oppenheimer raises CytomX stock price target on trial data
CytomX March 2026 slides: Varseta-M efficacy exceeds standard of care
Earnings call transcript: CytomX Therapeutics Q4 2025 highlights clinical progress